LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

Home・Listă Acțiuni・Quanterix Corp

Quanterix Corp

Închisă

SectorSănătate

3.5 -0.57

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.29

Maxim

3.54

Indicatori cheie
By Trading Economics
Venit	5.6M -18M
Vânzări	-7.4M 36M
EPS	0.16
Marjă de profit	-48.17
Angajați	450
EBITDA	1.5M -15M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+14.29% upside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	6.3M 165M
Deschiderea anterioară	4.07
Închiderea anterioară	3.5

Sentimentul știrilor

By Acuity

63%

37%

279 / 344 Clasament în Healthcare

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 iun. 2026, 20:30 UTC

Câștiguri

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 iun. 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 iun. 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 iun. 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 iun. 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 iun. 2026, 23:01 UTC

Achiziții, Fuziuni, Preluări

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 iun. 2026, 23:01 UTC

Achiziții, Fuziuni, Preluări

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 iun. 2026, 23:00 UTC

Achiziții, Fuziuni, Preluări

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 iun. 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 iun. 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 iun. 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 iun. 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 iun. 2026, 21:00 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 iun. 2026, 20:46 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:38 UTC

Câștiguri

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 iun. 2026, 20:21 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:12 UTC

Câștiguri

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Product Rev $594M

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 iun. 2026, 20:05 UTC

Câștiguri

Palo Alto Networks 3Q Loss $177M >PANW

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

14.29% sus

Prognoză pe 12 luni

Medie 4 USD 14.29%

Maxim 4 USD

Minim 4 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 2 analiști care au acordat evaluări ale acțiunilor Quanterix Corp - Dist în ultimele 3 luni.

Sentiment

By Acuity

279 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.